Fig. 5

The impact of patient cohort sizes. The patient cohort sizes were tested at 50, 100, 300, 600, and 800. The control cohort size was set at 5000. The percentage of patients carrying the pathogenic mutations of RPE65 or TINF2 was set at 2%. The performance of GRIPT, VAAST2, CMC, SKAT, and KBAC are shown in red, blue, green, purple, and orange, respectively. a The ranking of RPE65 under the AR model. b The power of the five tests for RPE65. c The number of significant autosomal candidates under the AR model. d The ranking of TINF2 under the AD model. e The power of the five tests for TINF2. f The number of significant autosomal candidates under the AD model. The rankings of RPE65/TINF2 generated by GRIPT were compared to those generated by the other four methods respectively with one-tailed WRST. The methods that generated significantly worse ranking than GRIPT were marked with “*” if p value < 0.05, “**” if p value < 0.01, and “***” if p value < 0.001